ACTU

Actuate Therapeutics Inc

8.67

0.07+0.81%

Closed16:04 06/11 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE8.66/8.60

TODAY RANGE8.32-8.82

VOL19.86K

MARKET CAP170.10M

52 WEEK RANGE5.51-11.99

AVG VOL (3M)58.59K

% TURNOVER0.10%

TURNOVER0

P/E (TTM)-6.7194

% RANGE5.78%

EPS(TTM)-1.2903

P/E(FORWARD)-7.5833

P/B-33.2822

BVPS-0.2605

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP137.35M

SHARES OUTSTANDING19.62M

NEXT EARNINGS--

FREE FLOAT15.84M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·6d ago
Actuate Therapeutics Hosts Key Opinion Leader Event
TipRanks·06/02 13:15
Actuate Therapeutics shares highlights from KOL eventon elraglusib data
Benzinga·06/02 13:04
Actuate Therapeutics Highlights Insights On Phase 2 Trial Results Showing Clinically Meaningful Survival Benefit And Favorable Safety Of Elraglusib Combined With Gemcitabine/Nab-Paclitaxel In Untreated Metastatic Pancreatic Cancer At KOL Event
TipRanks·06/02 11:57
Actuate Therapeutics Reports Positive Phase 2 Trial Results
Dow Jones·06/02 10:34
Actuate Therapeutics' Shares Gain on Positive Phase 2 Trial for Pancreatic Cancer Treatment
TipRanks·06/02 10:28
Promising Clinical Trial Results Justify Buy Rating for Actuate Therapeutics’ Elraglusib
Benzinga·06/02 08:06
Reported Saturday, Actuate's Elraglusib Meets Primary Endpoint In Phase 2 mPDAC Trial, Extending Median Overall Survival To 10.1 Months And Cutting Risk Of Death By 37%
Seeking Alpha·05/31 20:57
Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer
NASDAQ·05/31 20:40
Actuate Therapeutics Reports Positive Phase 2 Trial Results for Elraglusib in Metastatic Pancreatic Cancer, Improving Overall Survival
Reuters·05/31 20:30
ACTUATE THERAPEUTICS PRESENTS TOPLINE ELRAGLUSIB PHASE 2 DATA AT ASCO 2025 ANNUAL MEETING: TRIAL MEETS PRIMARY ENDPOINT OF MEDIAN OVERALL SURVIVAL AND DOUBLES 1-YEAR SURVIVAL IN FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER
TipRanks·05/23 20:32
Actuate Therapeutics Elects Directors at Annual Meeting
Benzinga·05/22 21:29
Actuate Therapeutics Announces Phase 2 Trial Success As Elraglusib Combo Shows Statistically Significant Survival Benefit In First-Line mPDAC, To Be Featured In ASCO 2025 Oral Presentation And Reviewed At May 31 KOL Event
Reuters·05/22 21:05
ACTUATE THERAPEUTICS ANNOUNCES DETAILS FOR 2025 ASCO ANNUAL MEETING PRESENTATION ON TOPLINE ELRAGLUSIB PHASE 2 DATA IN FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER
TipRanks·05/20 13:05
Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU)
Reuters·05/06 17:41
BUZZ-U.S. STOCKS ON THE MOVE-Leidos, Gartner, EVgo

Same Industry

Name/Symbol

Change%

Price

Regeneron Pharmaceuticals

REGN

-0.94%

518.60

Entero Therapeutics

ENTO

-3.16%

0.5704

BIONTECH

BNTX

-1.34%

105.46

United Therapeutics Corp.

UTHR

-1.74%

276.47

Vertex Pharmaceuticals Inc

VRTX

+0.20%

452.44

Siga Technologie

SIGA

+1.93%

6.34

Moderna

MRNA

+0.25%

27.75

Charles Riv Labs Intl Inc

CRL

+0.07%

151.11

Medpace Holdings

MEDP

-1.17%

302.31

Talphera Inc

TLPH

+0.57%

0.5130

ICON PLC

ICLR

+0.56%

145.54

China Biologic

CBPO

0.00%

119.99

Iqvia Hldgs Inc

IQV

-0.59%

158.83

MOLECULAR PARTNERS AG

MOLN

-2.35%

3.61

Arcturus Therape

ARCT

-3.57%

12.44

Gilead Sciences Inc

GILD

-0.72%

109.30

PRA Health

PRAH

0.00%

165.21

Incyte Corp

INCY

-1.74%

68.85

Aptevo Therapeutics Inc

APVO

-0.43%

4.65

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.